Our findings support further exploration of pharmacologic inhibition of CLK1 as a potential new treatment for obesity associated diabetes, beyond oncology, Duchenne muscular dystrophy and Alzheimer’s disease. The gene discussed is CLK1; the disease is Duchenne muscular dystrophy.